May 25, 2021 – The COPD Foundation announced that Midmark has recently joined the Foundation’s 2021 Corporate Partners Program.
The COPD Foundation began the corporate partners program in 2015 to interact with external organizations that have the shared goals of undertaking impactful initiatives relating to chronic obstructive pulmonary disease (COPD), bronchiectasis and nontuberculous mycobacterial (NTM) lung disease.
Midmark has a broad portfolio of solution-based products which address multiple point of care needs including patient positioning, infection prevention, medical device utilization, clinical workflow, and real-time location monitoring. The company is also active in clinical research with the aim to improve processes and look for next generation techniques and technologies.
Midmark has decades-long experience in providing spirometry/pulmonary function testing devices to both primary care physicians and specialists but also considers itself an “experience company focused on design” with the goal of reducing steps or burdens to improve the point of care experience for the patient and clinician.
“The population of patients with pulmonary diseases continues to grow and the need to improve outcomes at lower cost has never been more timely. Because COPD is a $40 billion-plus-dollar problem, the effort to improve the lives of patients and their caregivers and support health care providers is larger than any one company can do alone. It will take a team of experts, each with their own special area of contribution, to make it happen,” said Thomas Schwieterman, MD, MBA, chief medical officer and VP of clinical affairs at Midmark.
Midmark joins 23 other companies in the Foundation’s corporate partners program.